Cancer of Unknown Primary SiteOP-CUPNCT05841966
Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary
A study testing Transoral Ultrasound in people with Cancer of Unknown Primary Site and Unknown Primary Cancer, run by Copenhagen University Hospital, Rigshospitalet at 2 sites in Denmark.
Trial summary
Adult patients suspected of Squamous Cell Carcinoma of Unknown Primary (SCCUP) will be prospectively enrolled at a tertiary head \& neck cancer center at Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer of Unknown Primary Site, Unknown Primary Cancer, Unknown Primary, Squamous Cell Carcinoma
- What is being tested?
- Transoral Ultrasound
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 2 sitesDenmark
- Study dates
- 21 Feb 2023to 1 Mar 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Cytology-verified cervical lymph node metastasis from squamous cell carcinoma in neck levels I-IV with HPV+ cytology.
- Booked for panendoscopic examination under general anesthesia.
- Pre-operative MRI and PET-CT available.
Who cannot join
- Unable to provide written informed consent.
- Unable to complete full surgical work-up including palatine- and lingual tonsillectomy.
Trial locations and contacts
2 sites in 1 country.
Denmark2 sites
Århus University Hospital, Department of Otorhinolaryngology, Head & Neck Surgery
Aarhus, 8200
Rigshospitalet, Department of Otorhinolaryngology, Head & Neck Surgery & Audiology
Copenhagen, 2100
About this study
Official title: Surgeon-performed Intraoperative Transoral Ultrasound in Patients With Suspected Head and Neck Squamous Cell Carcinoma of Unknown Primary: a Prospective Diagnostic Accuracy Study
Adult patients suspected of Squamous Cell Carcinoma of Unknown Primary (SCCUP) will be prospectively enrolled at a tertiary head \& neck cancer center at Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. All patients will undergo Magnetic Resonance Imaging (MRI) and Positron Emission Tomography-Computerized Tomography (PET-CT) prior to examination in general anesthesia. During general anesthesia, Intraoperative Transoral Ultrasound (ITUS) will be performed prior to panendoscopy. Detected tumors will be registered with specified oropharyngeal sub-locations. Blinded to ITUS, a consultant head \& neck surgeon will perform panendoscopy. After examination, the surgeon is unblinded to ultrasound results. Final histopathology results from location-specified biopsies performed will be used as reference standard. The overall detection rate will be compared between ITUS, panendoscopy, PET-CT and MRI with sensitivity and specificity analysis. Oropharynx sub-location specific detection rate of ITUS vs. panendoscopy will be compared with logistic regression analysis.
Read the detailed description
A prospective diagnostic study examining patients with suspected SCCUP will be performed at the Department of Otorhinolaryngology \& Head \& Neck Surgery, Copenhagen University Hospital - Rigshospitalet, Denmark. This specialized cancer center is responsible for the surgical work-up for approximately half of suspected SCCUP patients in the Danish population of 5.8 million.
Standard work-up of patients with suspected SCCUP in Denmark consists of same-day clinical examination combined with high resolution video endoscopy with NBI, surgeon-performed neck ultrasound and fine-needle aspiration cytology (FNAC) of suspected lymph nodes with same-day results. Cytology results can be further tested for Human Papillomavirus (HPV), and patients are booked for panendoscopic examination under general anesthesia with frozen section biopsy. Pre-operative cross-sectional imaging to locate the primary tumor includes MRI and 18-F Fluordeoxyglucose (FDG) PET-CT.
Intraoperative transoral ultrasound
During general anesthesia and prior to panendoscopy, ITUS will be performed while a consultant head \& neck surgeon performing panendoscopy is blinded. A Fujifilm Arietta 850 or Arietta 65 (Fujifilm, Tokyo, Japan), BK5000 (BK Medical ApS, Herlev, Denmark), or Samsung RS85 (Samsung Medison, Seoul, South Korea) ultrasound machines will be used. Small-footprint, high-frequency transducers such as the Arietta L51K linear-array intraoperative robot transducer attached to a forceps, the BK5000 "flexible hockey-stick" 18XL5s, or the Samsung RS85 LA3-22AI "hockeystick" will be used. A Boyle-Davis gag or laryngoscope will be used to visualize the tonsils (Figure 1), while the transducer is placed onto each tonsil in transverse and sagittal planes. The tongue base will be scanned by pulling the tongue anteriorly by an assistant and placing the transducer directly onto the tongue base. Alternatively, the tongue can be retracted with a video-laryngoscope while revealing the tongue base. The tongue base will be scanned from side to side in the sagittal plane. The tongue can then be pulled to either the left or right side to angle the probe obliquely for transverse imaging. If a tumor is suspected, the tumor location is registered in the following categories, including indication of right or left side:
- Tonsil cranial.
- Tonsil caudal.
- Glossotonsillar sulcus.
- Anterolateral tongue base.
- Anteromedial tongue base.
- Posterolateral tongue base.
- Posteromedial tongue base.
- "Other" oropharynx sub-locations, including anterior \& posterior pharyngeal arches, soft palate, uvula, posterior oropharynx wall, and vallecula.
B-mode video clips of both tonsils and the tongue base will be recorded. Power doppler for suspected tumors and the contralateral side will be performed. If a well-defined lesion is seen, the greatest tumor diameter and if possible, three-dimensional size is measured. The grade of tumor suspicion will be rated on a 5-point Likert scale ranging from 0 (very low) to 5 (very high).
Panendoscopy Following ITUS, the surgeon will perform standard panendoscopy of the pharynx including palpation of the oral cavity and oropharynx, and high-resolution video endoscopy with NBI. If the surgeon suspects a tumor, the location is registered with the same categories as above. Tumor suspicion will be rated on a 5-point Likert scale ranging from 0 (very low) to 5 (very high). The surgeon will categorize visual findings such as ulcers, exophytic tumors, asymmetric tissue, vulnerable/bleeding mucosa, suspect vasculature on NBI, or no suspect visual findings. The surgeon will categorize palpatory findings as soft or firm. The clinically visualized or palpated greatest tumor diameter will be estimated. The surgeon is then unblinded to ultrasound results. After unblinding from ultrasound, the investigators will register whether further directed biopsies from ultrasound suspected location are performed.
If the primary tumor is not located during panendoscopy, patients will tonsillectomied and the tonsils will be sliced in 2mm slices by head \& neck pathologists in search of the primary tumor. If the primary tumor is still unknown and the neck metastasis is HPV+, then patients are offered Transoral Robotic Surgery (TORS) with diagnostic tongue base mucosectomy. These tongue base specimens will also be sliced in 2mm slices and examined by head \& neck pathologists. If the primary tumor is located in final histopathology from either tonsillectomies or tongue base mucosectomy, the location of the tumors will be compared to the initially registered suspected ultrasound locations from panendoscopy.
Medical chart data The patient's age, sex, alcohol, smoking, largest cervical lymph node size, cervical lymph node side (right/left), date of panendoscopy, date of conclusive histopathology results, and date of treatment initiation will be obtained from medical charts.
- Conditions
- Cancer of Unknown Primary Site, Unknown Primary Cancer, Unknown Primary, Squamous Cell Carcinoma
- Being tested
- Transoral Ultrasound
- Medical subject headings
- Neoplasms, Unknown Primary, Carcinoma, Squamous Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transoral UltrasoundDiagnostic test
The tonsils and tongue base will be scanned transorally using high-frequency intraoperative ultrasound transducers. Direct contact with the tonsils through the mouth is achieved during general anesthesia.
| Study group | Role | What they receive |
|---|---|---|
| Intraoperative Transoral Ultrasound | Experimental | Transoral ultrasound of the tonsils and tongue base under general anesthesia. Receives: Diagnostic Test: Transoral Ultrasound |
What is being measured
The primary outcome is the main question the study is designed to answer.
Increased detection rate by adding ITUS to panendoscopy
The difference in proportion of patients with SCCUP where a primary tumor location is correctly detected by ITUS but not detected with panendoscopy alone.
Measured: Within 2-4 weeks after panendoscopy.
Secondary outcomes (2)
Ultrasonographic features of primary tonsil and tongue base tumors
The echogenicity, shape and doppler flow pattern relative to the normal and contralateral tonsil tissue will be compared in biopsy-verified primary tumors.
Measured: 1 year
Comparison of detection rate of ITUS, panendoscopy, combined ITUS+panendoscopy, MRI and PET-CT for locating the primary tumor.
The percentage of primary tumors located is compared between all of the above tests.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2023
- Study start21 Feb 2023
- Primary completion29 Jan 2024
- Study completion1 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer of Unknown Primary SiteStudies of the same condition, open and under way.
- More trials run by Copenhagen University Hospital, RigshospitaletThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Sponsor type
- University, hospital or other
- Collaborators
- The Novo Nordic Foundation
- Responsible party
- Principal investigator, Martin Garset-Zamani, MD, Copenhagen University Hospital, Rigshospitalet
- Investigators
- Tobias Todsen, MD, PhD, Study director, Copenhagen University Hospital, Rigshospitalet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05841966
- Sponsor's protocol ID
- Unknown Primary Transoral US
- Acronym
- OP-CUP
- Status last verified
- May 2024
- First submitted
- 16 Feb 2023
- Last updated
- 7 May 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Surgeon-performed Intraoperative Transoral Ultrasound in Patients With Suspected Head and Neck Squamous Cell Carcinoma of Unknown Primary: a Prospective Diagnostic Accuracy Study
- ClinicalTrials.gov ID
- NCT05841966
- Acronym / sponsor ID
- OP-CUP / Unknown Primary Transoral US
- Conditions
- Cancer of Unknown Primary Site, Unknown Primary Cancer, Unknown Primary, Squamous Cell Carcinoma
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletUniversity, hospital or other
- Collaborators
- The Novo Nordic Foundation
- Study start
- 21 Feb 2023 (actual)
- Primary completion
- 29 Jan 2024 (actual)
- Study completion
- 1 Mar 2024 (actual)
- First posted
- 3 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adult patients suspected of Squamous Cell Carcinoma of Unknown Primary (SCCUP) will be prospectively enrolled at a tertiary head \& neck cancer center at Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. All patients will undergo Magnetic Resonance Imaging (MRI) and Positron Emission Tomography-Computerized Tomography (PET-CT) prior to examination in general anesthesia. During general anesthesia, Intraoperative Transoral Ultrasound (ITUS) will be performed prior to panendoscopy. Detected tumors will be registered with specified oropharyngeal sub-locations. Blinded to ITUS, a consultant head \& neck surgeon will perform panendoscopy. After examination, the surgeon is unblinded to ultrasound results. Final histopathology results from location-specified biopsies performed will be used as reference standard. The overall detection rate will be compared between ITUS, panendoscopy, PET-CT and MRI with sensitivity and specificity analysis. Oropharynx sub-location specific detection rate of ITUS vs. panendoscopy will be compared with logistic regression analysis.
Detailed description
A prospective diagnostic study examining patients with suspected SCCUP will be performed at the Department of Otorhinolaryngology \& Head \& Neck Surgery, Copenhagen University Hospital - Rigshospitalet, Denmark. This specialized cancer center is responsible for the surgical work-up for approximately half of suspected SCCUP patients in the Danish population of 5.8 million.
Standard work-up of patients with suspected SCCUP in Denmark consists of same-day clinical examination combined with high resolution video endoscopy with NBI, surgeon-performed neck ultrasound and fine-needle aspiration cytology (FNAC) of suspected lymph nodes with same-day results. Cytology results can be further tested for Human Papillomavirus (HPV), and patients are booked for panendoscopic examination under general anesthesia with frozen section biopsy. Pre-operative cross-sectional imaging to locate the primary tumor includes MRI and 18-F Fluordeoxyglucose (FDG) PET-CT.
Intraoperative transoral ultrasound
During general anesthesia and prior to panendoscopy, ITUS will be performed while a consultant head \& neck surgeon performing panendoscopy is blinded. A Fujifilm Arietta 850 or Arietta 65 (Fujifilm, Tokyo, Japan), BK5000 (BK Medical ApS, Herlev, Denmark), or Samsung RS85 (Samsung Medison, Seoul, South Korea) ultrasound machines will be used. Small-footprint, high-frequency transducers such as the Arietta L51K linear-array intraoperative robot transducer attached to a forceps, the BK5000 "flexible hockey-stick" 18XL5s, or the Samsung RS85 LA3-22AI "hockeystick" will be used. A Boyle-Davis gag or laryngoscope will be used to visualize the tonsils (Figure 1), while the transducer is placed onto each tonsil in transverse and sagittal planes. The tongue base will be scanned by pulling the tongue anteriorly by an assistant and placing the transducer directly onto the tongue base. Alternatively, the tongue can be retracted with a video-laryngoscope while revealing the tongue base. The tongue base will be scanned from side to side in the sagittal plane. The tongue can then be pulled to either the left or right side to angle the probe obliquely for transverse imaging. If a tumor is suspected, the tumor location is registered in the following categories, including indication of right or left side:
- Tonsil cranial.
- Tonsil caudal.
- Glossotonsillar sulcus.
- Anterolateral tongue base.
- Anteromedial tongue base.
- Posterolateral tongue base.
- Posteromedial tongue base.
- "Other" oropharynx sub-locations, including anterior \& posterior pharyngeal arches, soft palate, uvula, posterior oropharynx wall, and vallecula.
B-mode video clips of both tonsils and the tongue base will be recorded. Power doppler for suspected tumors and the contralateral side will be performed. If a well-defined lesion is seen, the greatest tumor diameter and if possible, three-dimensional size is measured. The grade of tumor suspicion will be rated on a 5-point Likert scale ranging from 0 (very low) to 5 (very high).
Panendoscopy Following ITUS, the surgeon will perform standard panendoscopy of the pharynx including palpation of the oral cavity and oropharynx, and high-resolution video endoscopy with NBI. If the surgeon suspects a tumor, the location is registered with the same categories as above. Tumor suspicion will be rated on a 5-point Likert scale ranging from 0 (very low) to 5 (very high). The surgeon will categorize visual findings such as ulcers, exophytic tumors, asymmetric tissue, vulnerable/bleeding mucosa, suspect vasculature on NBI, or no suspect visual findings. The surgeon will categorize palpatory findings as soft or firm. The clinically visualized or palpated greatest tumor diameter will be estimated. The surgeon is then unblinded to ultrasound results. After unblinding from ultrasound, the investigators will register whether further directed biopsies from ultrasound suspected location are performed.
If the primary tumor is not located during panendoscopy, patients will tonsillectomied and the tonsils will be sliced in 2mm slices by head \& neck pathologists in search of the primary tumor. If the primary tumor is still unknown and the neck metastasis is HPV+, then patients are offered Transoral Robotic Surgery (TORS) with diagnostic tongue base mucosectomy. These tongue base specimens will also be sliced in 2mm slices and examined by head \& neck pathologists. If the primary tumor is located in final histopathology from either tonsillectomies or tongue base mucosectomy, the location of the tumors will be compared to the initially registered suspected ultrasound locations from panendoscopy.
Medical chart data The patient's age, sex, alcohol, smoking, largest cervical lymph node size, cervical lymph node side (right/left), date of panendoscopy, date of conclusive histopathology results, and date of treatment initiation will be obtained from medical charts.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intraoperative Transoral Ultrasound | Experimental | Diagnostic Test: Transoral UltrasoundTransoral ultrasound of the tonsils and tongue base under general anesthesia. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Cytology-verified cervical lymph node metastasis from squamous cell carcinoma in neck levels I-IV with HPV+ cytology.
- Booked for panendoscopic examination under general anesthesia.
- Pre-operative MRI and PET-CT available.
Key exclusion criteria (2 listed)
- Unable to provide written informed consent.
- Unable to complete full surgical work-up including palatine- and lingual tonsillectomy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transoral UltrasoundThe tonsils and tongue base will be scanned transorally using high-frequency intraoperative ultrasound transducers. Direct contact with the tonsils through the mouth is achieved during general anesthesia. | Diagnostic test | Intraoperative Transoral Ultrasound |
Primary outcome
Increased detection rate by adding ITUS to panendoscopy
Time frame: Within 2-4 weeks after panendoscopy.
The difference in proportion of patients with SCCUP where a primary tumor location is correctly detected by ITUS but not detected with panendoscopy alone.
2 secondary outcomes
Ultrasonographic features of primary tonsil and tongue base tumors
Time frame: 1 year
Comparison of detection rate of ITUS, panendoscopy, combined ITUS+panendoscopy, MRI and PET-CT for locating the primary tumor.
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 May 2024.
- Individual participant dataSharing planned: No
Related trials for Cancer of Unknown Primary Site
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingPhase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Recruiting
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Ampulla of Vater Carcinoma, Appendix Carcinoma
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruiting
Smartphone-Based Self-Registration of Health Data in Patients With Severe Unspecific Symptoms or Cancer of Unknown Primary
Advanced Unspecific Symptom, Cancer of Unknown Primary Site
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tobias Todsen, MD, PhD study director
Copenhagen University Hospital, Rigshospitalet
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transoral Ultrasound in people with Cancer of Unknown Primary Site and Unknown Primary Cancer, run by Copenhagen University Hospital, Rigshospitalet at 2 sites in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Increased detection rate by adding ITUS to panendoscopy (time frame: Within 2-4 weeks after panendoscopy.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2024.